Roche Board Update: Claudia Süssmuth Dyckerhoff Steps Down

Key highlights
  • Dr. Claudia Süssmuth Dyckerhoff will not seek re-election to Roche's Board in 2026.
  • She will be nominated for a board position at another healthcare company.
  • Dr. Süssmuth Dyckerhoff has been on Roche's Board since March 2016.

Board Departure

Dr. Claudia Süssmuth Dyckerhoff has announced she will not stand for re-election to the Roche Board of Directors at the Annual General Meeting in 2026. Instead, she will be nominated for a board position at another company within the healthcare industry.

Tenure at Roche

Dr. Süssmuth Dyckerhoff has been a member of the Roche Board since March 2016. Her expertise in the healthcare sector and understanding of international market dynamics, especially in Asia, have been valuable to Roche's success.

Chairman's Remarks

Roche Chairman Severin Schwan expressed gratitude for Dr. Süssmuth Dyckerhoff's contributions, highlighting her profound industry knowledge and dedication over the past decade.

Source: Roche

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

1 October 2026
Roche: VOYAGER real‑world data confirm Vabysmo effectiveness and safety in nAMD, DME and RVO

VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.

10 September 2026
Roche: FDA grants Priority Review for Enspryng in MOGAD

FDA to decide by 10 Jan 2027 on satralizumab for MOGAD after Phase III METEOROID showed 68% relapse risk reduction; EMA validation pending EC decision in Q3 2027.

9 September 2026
Chugai researchers win Lasker-DeBakey Award for emicizumab discovery

Three researchers honoured for creating a bispecific antibody that mimics Factor VIII, enabling subcutaneous dosing and bleed prevention irrespective of inhibitors.

9 September 2026
Genentech: FDA grants Priority Review for Enspryng in MOGAD

Priority Review follows Phase III METEOROID showing 68% relapse risk reduction; FDA decision expected Jan 10, 2027; EMA validated the MOGAD filing with EC decision due Q3 2027.

15 July 2026
Roche: FDA grants Priority Review for Gazyva/Gazyvaro (obinutuzumab) in primary membranous nephropathy

Priority Review follows MAJESTY phase III showing 36.9% complete remission at two years vs 5.7% with tacrolimus; FDA decision expected by Nov 2026.